Interferon News and Research

RSS

Interferon Type I immune proteins key drivers of human hemorrhagic fevers

Hemorrhagic fevers caused by Lassa, dengue and other viruses affect more than one million people annually and are often fatal, yet scientists have never understood why only some virus-infected people come down with the disease and others do not.

5 Jun 2014

Biomedical scientists explore mechanisms of novel treatments for HCV

As new treatments for hepatitis C virus (HCV) are approved, biomedical scientists are exploring their mechanisms and what they reveal about the virus.

29 May 2014

Ebola research: an interview with Professor Easton, University of Warwick

Ebola virus belongs to a group of viruses that have been known for some time. It was first isolated as a result of an infection in a primate, in a monkey colony, in monkeys that were being used for research in the Philippines.

28 May 2014

Merck Serono launches web-based software system for MS patients receiving Rebif treatment

A new web and app-based software solution, launched in the UK today on World MS Day, will allow physicians and nurses to monitor treatment of patients taking MS disease-modifying treatment Rebif by collecting injection history through the new RebiSmart 2.0 electronic autoinjector.

28 May 2014

Researchers resolve long-standing mystery of enzyme's role in cell survival

St. Jude Children's Research Hospital solves mystery of enzyme's role in cell survival, offering clues of how immune system fights infection and possible strategies to treat problems ranging from heart attack to cancer.

23 May 2014

OLYSIO (simeprevir) receives EC marketing authorisation for treatment of genotype 1 and 4 CHC

Janssen-Cilag International NV today announced that its next generation protease inhibitor (PI) OLYSIOTM (simeprevir) has been granted marketing authorisation by the European Commission (EC) for the treatment of adults with genotype 1 and 4 chronic hepatitis C (CHC), in combination with other medicinal products.

16 May 2014

Inflammation may accentuate age-related bladder function decline

Age-associated biochemical changes in the bladder may accentuate the inflammation associated with overactive bladder, study findings indicate.

12 May 2014

AbbVie seeks marketing approval from EMA for all-oral, interferon-free therapy to treat HCV infection

AbbVie submitted marketing authorization applications (MAAs) to the European Medicines Agency seeking approval for the company’s investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection.

9 May 2014

Janssen submits sNDA to FDA for simeprevir in combination with sofosbuvir for treatment of HCV genotype 1 infection

Janssen Research & Development, LLC (Janssen) today announced it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for simeprevir, an NS3/4A protease inhibitor marketed as OLYSIO™ in the United States, in combination with the nucleotide analog NS5B polymerase inhibitor sofosbuvir developed by Gilead Sciences, Inc.

8 May 2014

New two-year data from Biogen Idec’s Phase 3 trial for peginterferon beta-1a presented at AAN annual meeting

New two-year data from the Phase 3 ADVANCE clinical trial for peginterferon beta-1a in adults with relapsing forms of multiple sclerosis (RMS) has been presented at the 66th American Academy of Neurology (AAN) annual meeting.

5 May 2014

Study: New combination therapy to treat chronic hepatitis C

A new combination therapy allows chronic hepatitis C to be treated in a manner that is less aggressive yet equally efficient.

5 May 2014

New data from EMD Serono's multiple sclerosis portfolio to be presented at the 66th AAN Annual Meeting

EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, announced today that new data from the company's multiple sclerosis (MS) portfolio will be presented at the American Academy of Neurology's 66th Annual Meeting, taking place from April 26 – May 3, in Philadelphia, PA.

26 Apr 2014

Sunitinib-related fatigue occurs early then tails off during RCC treatment

Patients beginning sunitinib treatment for advanced renal cell carcinoma should be warned that fatigue is likely to occur early, but that it is unlikely to worsen over the course of treatment, suggest US researchers in Cancer.

22 Apr 2014

Researchers identify mechanism that explains reason for persistence of hepatitis C virus

Researchers at the University of California, San Diego School of Medicine have identified a mechanism that explains why people with the hepatitis C virus get liver disease and why the virus is able to persist in the body for so long.

16 Apr 2014

Optimal use of combination therapy achieves best treatment outcomes in patients with CHB

Three new studies presented today at the International Liver CongressTM 2014 have helped clarify the optimal use of combination therapy with peginterferon and nucleoside analogues (NUCs) to achieve the best treatment outcomes in patients with chronic hepatitis B (CHB).

16 Apr 2014

New drug combination proves effective in treating patients with HCV genotype 1

Treatment options for the 170 million people worldwide with chronic Hepatitis C Virus (HCV) are evolving rapidly, although the available regimens often come with significant side effects. Two multi-center clinical trials led by Beth Israel Deaconess Medical Center show promise for a new option that could help lead to both an increase in patients cured with a much more simple and tolerable all oral therapy.

15 Apr 2014

Oral therapy cures hepatitis C infection in more than 90% of patients with liver cirrhosis

Twelve weeks of an investigational oral therapy cured hepatitis C infection in more than 90 percent of patients with liver cirrhosis and was well tolerated by these patients, according to an international study that included researchers from UT Medicine San Antonio and the Texas Liver Institute.

15 Apr 2014

New research provides new hope for liver transplant patients with recurring hepatitis C

New research announced at the International Liver CongressTM 2014 today provides new hope for the notoriously difficult-to-treat population of liver transplant patients with recurring hepatitis C (HCV).

11 Apr 2014

Scientists discover protein potentially good target for influenza A virus

Scientists at The University of Texas at Austin have discovered that a protein produced by the influenza A virus helps it outwit one of our body's natural defense mechanisms. That makes the protein a potentially good target for antiviral drugs directed against the influenza A virus.

11 Apr 2014

Scientists identify enzyme that could be a useful target in treating asthma, cancer

In experiments with mice, Johns Hopkins Kimmel Cancer Center scientists have identified an enzyme involved in the regulation of immune system T cells that could be a useful target in treating asthma and boosting the effects of certain cancer therapies.

11 Apr 2014

Interferon News and Research

Interferon Type I immune proteins key drivers of human hemorrhagic fevers

Biomedical scientists explore mechanisms of novel treatments for HCV

Ebola research: an interview with Professor Easton, University of Warwick

Merck Serono launches web-based software system for MS patients receiving Rebif treatment

Researchers resolve long-standing mystery of enzyme's role in cell survival

OLYSIO (simeprevir) receives EC marketing authorisation for treatment of genotype 1 and 4 CHC

Inflammation may accentuate age-related bladder function decline

AbbVie seeks marketing approval from EMA for all-oral, interferon-free therapy to treat HCV infection

Janssen submits sNDA to FDA for simeprevir in combination with sofosbuvir for treatment of HCV genotype 1 infection

New two-year data from Biogen Idec’s Phase 3 trial for peginterferon beta-1a presented at AAN annual meeting

Study: New combination therapy to treat chronic hepatitis C

New data from EMD Serono's multiple sclerosis portfolio to be presented at the 66th AAN Annual Meeting

Sunitinib-related fatigue occurs early then tails off during RCC treatment

Researchers identify mechanism that explains reason for persistence of hepatitis C virus

Optimal use of combination therapy achieves best treatment outcomes in patients with CHB

New drug combination proves effective in treating patients with HCV genotype 1

Oral therapy cures hepatitis C infection in more than 90% of patients with liver cirrhosis

New research provides new hope for liver transplant patients with recurring hepatitis C

Scientists discover protein potentially good target for influenza A virus

Scientists identify enzyme that could be a useful target in treating asthma, cancer

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News